Review
doi: 10.1038/sj.eye.6702501.
Epub 2006 Jul 21.
Bevacizumab: a new way of doing business?
Affiliations
- PMID: 16858443
- DOI: 10.1038/sj.eye.6702501
Item in Clipboard
Review
Bevacizumab: a new way of doing business?
Eye (Lond).
2006 Sep.
Abstract
This review highlights the history of the development of treatments for choroidal neovascularization (wct AMD). It examines how drug therapies have evolved for the management of age-related macular degeneration (AMD) and the value of randomised clinical trials in determining efficacy. Finally it examines the emerging practice of utilising bevacizumab for the treatment of choroidal neovascularization despite the lack of any phase III clinical trial data.
Comment in
-
Bevacizumab: a compassionate way of doing business?Eye (Lond). 2007 Jun;21(6):890-1; author reply 891. doi: 10.1038/sj.eye.6702776. Epub 2007 Mar 16. Eye (Lond). 2007. PMID: 17363924 No abstract available.
Similar articles
-
Bevacizumab: a compassionate way of doing business?Eye (Lond). 2007 Jun;21(6):890-1; author reply 891. doi: 10.1038/sj.eye.6702776. Epub 2007 Mar 16. Eye (Lond). 2007. PMID: 17363924 No abstract available.
-
Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.Semin Ophthalmol. 2011 May;26(3):69-76. doi: 10.3109/08820538.2010.545100. Semin Ophthalmol. 2011. PMID: 21609219 Review.
-
Avastin and new treatments for AMD: where are we?Retina. 2006 Oct;26(8):853-8. doi: 10.1097/01.iae.0000244722.35073.7c. Retina. 2006. PMID: 17031283 Review. No abstract available.
-
Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.Acta Ophthalmol Scand. 2006 Oct;84(5):713-4. doi: 10.1111/j.1600-0420.2006.00759.x. Acta Ophthalmol Scand. 2006. PMID: 16965511 No abstract available.
-
Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.Curr Opin Ophthalmol. 2011 May;22(3):152-8. doi: 10.1097/ICU.0b013e32834595d0. Curr Opin Ophthalmol. 2011. PMID: 21483262 Review.
Cited by
-
Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?Drugs Aging. 2009;26(4):295-320. doi: 10.2165/00002512-200926040-00002. Drugs Aging. 2009. PMID: 19476398 Review.
-
Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.Br J Ophthalmol. 2007 Sep;91(9):1177-82. doi: 10.1136/bjo.2007.118562. Epub 2007 May 2. Br J Ophthalmol. 2007. PMID: 17475698 Free PMC article.
-
Bevacizumab: a new way of doing business. Part 2.Eye (Lond). 2019 Apr;33(4):519-520. doi: 10.1038/s41433-018-0281-2. Epub 2018 Nov 27. Eye (Lond). 2019. PMID: 30482906 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
